2020
Effect of High Fructose Corn Sirup on Pancreatic Ductal Adenocarcinoma Induced by Dimethyl Benzantracene (DMBA) in Rats
Ozcan-Sınır G, Inan S, Suna S, Tamer CE, Akgül MB, Bagdas D, Sonmez G, Evrensel T, Kaya E, Sarandol E, Dündar HZ, Tarım OF, Ercan I, Sıgırlı D, Incedayı B, Copur OU. Effect of High Fructose Corn Sirup on Pancreatic Ductal Adenocarcinoma Induced by Dimethyl Benzantracene (DMBA) in Rats. Nutrition And Cancer 2020, 73: 339-349. PMID: 32475178, DOI: 10.1080/01635581.2020.1770811.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaMale Sprague-Dawley ratsDevelopment of PDACSprague-Dawley ratsConsumption of sugarHistopathologic findingsPancreatic cancerDawley ratsDuctal adenocarcinomaRat modelGlucose levelsChow consumptionBody weightHistologic specimensDifferentiated typeDimethyl benzanthraceneDaily intakeRatsEntire groupTissue processing protocolChowTumor formationSignificant differencesFeeding periodGroup
2019
Brief report: the disability of chronic chikungunya arthritis
Amaral JK, Bilsborrow JB, Schoen RT. Brief report: the disability of chronic chikungunya arthritis. Clinical Rheumatology 2019, 38: 2011-2014. PMID: 30963336, PMCID: PMC7400963, DOI: 10.1007/s10067-019-04529-x.Peer-Reviewed Original ResearchConceptsChikungunya feverHealth Assessment Questionnaire Disability IndexPain visual analog scaleChronic chikungunya arthritisHAQ-DI scoresVisual analog scaleSpectrum of painChikungunya arthritisDisability IndexRheumatology clinicRheumatic diseasesAnalog scaleArthritic painDisability levelCCA patientsModerate disabilityPatientsPainEntire groupArthritisMean scoreDisabilityScoresUrgent needMorbidity
2016
MPTH-34. THE PROGNOSTIC VALUE OF POLYSOMY IN OLIGODENDROGLIAL TUMORS
Chen H, Thomas C, Munoz F, Alexandrescu S, Horbinski C, Olar A, McGuone D, Camelo-Piragua S, Wang L, Pentsova E, Phillips J, Aldape K, Iafrate A, Golfinos J, Chi A, Zagzag D, Rosenblum M, Ohman-Strickland P, Hameed M, Snuderl M. MPTH-34. THE PROGNOSTIC VALUE OF POLYSOMY IN OLIGODENDROGLIAL TUMORS. Neuro-Oncology 2016, 18: vi113-vi113. DOI: 10.1093/neuonc/now212.471.Peer-Reviewed Original ResearchProgression-free survivalOverall survivalOligodendroglial tumorsBetter progression-free survivalShorter progression-free survivalGroup of patientsSignificant differencesCommon molecular testsFree survivalFavorable prognosisEarly recurrenceShorter survivalPrognostic significancePrognostic valueAnaplastic oligodendrogliomaBrain tumorsTumorsEntire groupMolecular testsCytogenetic patternDeletion statusHallmark featureSurvivalPatientsPolysomy
2006
Healthcare Utilization in Women with Obstructive Sleep Apnea Syndrome 2 Years After Diagnosis and Treatment
Banno K, Manfreda J, Walld R, Delaive K, Kryger MH. Healthcare Utilization in Women with Obstructive Sleep Apnea Syndrome 2 Years After Diagnosis and Treatment. Sleep 2006, 29: 1307-1311. PMID: 17068984, DOI: 10.1093/sleep/29.10.1307.Peer-Reviewed Original ResearchConceptsObstructive sleep apnea syndromeContinuous positive airway pressureClinic visitsHealthcare utilizationWeight lossTertiary university-based medical centerRetrospective observational cohort studyEntire groupUniversity-based medical centerTreatment-compliant patientsObservational cohort studyPositive airway pressureSleep apnea syndromeAirway pressureCohort studyCompliant patientsApnea syndromePhysician claimsMedical CenterWL groupGeneral populationPatientsDiagnosisVisitsWomenSkeletal related events (SREs) in metastatic androgen independent prostate cancer (AIPC) treated with docetaxel-based chemotherapy: Results from ASCENT
Chan J, Ryan C, Venner P, Petrylak D, Chatta G, Ruether J, Chi K, Young J, Shen C, Beer T. Skeletal related events (SREs) in metastatic androgen independent prostate cancer (AIPC) treated with docetaxel-based chemotherapy: Results from ASCENT. Journal Of Clinical Oncology 2006, 24: 4614-4614. DOI: 10.1200/jco.2006.24.18_suppl.4614.Peer-Reviewed Original ResearchAndrogen-independent prostate cancerSkeletal related eventsSRE-free survivalMetastatic androgen-independent prostate cancerDocetaxel-based chemotherapyZoledronic acidDN-101SRE incidenceZA useRisk of SREsDocetaxel-based therapySpinal cord compressionRandomized clinical trialsIndependent prostate cancerAIPC patientsCord compressionProlong survivalProspective studyClinical trialsModern chemotherapyProstate cancerPatientsCochran-MantelChemotherapyEntire group
2005
Anthropometric and psychosocial changes in obese adolescents enrolled in a Weight Management Program
Savoye M, Berry D, Dziura J, Shaw M, Serrecchia JB, Barbetta G, Rose P, Lavietes S, Caprio S. Anthropometric and psychosocial changes in obese adolescents enrolled in a Weight Management Program. Journal Of The Academy Of Nutrition And Dietetics 2005, 105: 364-370. PMID: 15746823, DOI: 10.1016/j.jada.2004.12.009.Peer-Reviewed Original ResearchConceptsBMI z-scoreWeight management programBody fat percentNondiet approachObese adolescentsZ-scoreComprehensive weight management programSuperior short-term resultsBody mass index z-scoreEntire groupFat percentStructured meal planImproved long-term resultsLong-term resultsIndex z-scoreShort-term resultsBetter food choicesDietary ApproachesLong-term effectsCovariance pattern modelMeal planPsychosocial changesOutcome variablesManagement programScores
1996
Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma
Wilson L, Quiros P, Kolenik S, Heald P, Braverman I, Edelson R, Kacinski B. Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. Journal Of The American Academy Of Dermatology 1996, 35: 69-73. PMID: 8682967, DOI: 10.1016/s0190-9622(96)90499-5.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyCutaneous T-cell lymphomaRecurrent cutaneous T-cell lymphomaComplete responseT-cell lymphomaElectron beam therapySecond courseMedian disease-free intervalThird courseAdditional coursesBeam therapyDisease-free intervalTreatment of patientsAcceptable risk profileForm of therapyMedian doseMedian survivalMild erythemaPatientsInitial courseTherapyVariety of modalitiesRisk profileEntire groupLocalized radiation
1993
Dopamine D2 receptor density estimates in schizophrenia: A positron emission tomography study with11C-N-methylspiperone
Tune L, Wong D, Pearlson G, Strauss M, Young T, Shaya E, Dannals R, Wilson A, Ravert H, Sapp J, Cooper T, Chase G, Wagner H. Dopamine D2 receptor density estimates in schizophrenia: A positron emission tomography study with11C-N-methylspiperone. Psychiatry Research 1993, 49: 219-237. PMID: 7909948, DOI: 10.1016/0165-1781(93)90063-m.Peer-Reviewed Original ResearchConceptsPositron emission tomographySchizophrenic patientsBmax valuesEntire groupControl subjectsEmission tomographyDopamine D2 receptor densityNeuroleptic-free patientsDuration of illnessChronic schizophrenic patientsD2 receptor densityClinical characteristicsPatient populationReceptor abnormalitiesCorpus striatumClinical dataReceptor densityPatientsControl groupFunction of ageLate manifestationDifferent radioligandsFour-compartment modelSignificant differencesRadioligand
1991
The Noncemented Porous-Coated Hip Prosthesis
BANDS R, PELKER R, SHINE J, BRADBURN H, MARGOLIS R, LEACH J. The Noncemented Porous-Coated Hip Prosthesis. Clinical Orthopaedics And Related Research® 1991, 269: 209-219. PMID: 1864041, DOI: 10.1097/00003086-199108000-00030.Peer-Reviewed Original ResearchConceptsTotal hip arthroplastyPorous-coated componentsFemoral stemHip arthroplastyMean Harris hip scorePorous-coated femoral stemDistal cortical hypertrophyHarris hip scoreExcellent resultsBipolar acetabular componentMean followPorous-coated femoralHip scoreThigh painRoentgenographic findingsCortical hypertrophyRetrospective studyRoentgenographic changesProximal femurBipolar endoprosthesesEntire groupAcetabular componentPatientsBone bridgingArthroplasty
1988
Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support.
Shea TC, Antman KH, Eder JP, Elias A, Peters WP, Schryber S, Henner WD, Schoenfeld DA, Schnipper LE, Frei E. Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support. JAMA Dermatology 1988, 124: 878-84. PMID: 3288124, DOI: 10.1001/archderm.124.6.878.Peer-Reviewed Original ResearchConceptsAutologous bone marrow supportBone marrow supportHigh-dose combinationMarrow supportAgent chemotherapyPhase 2 doseMetastatic malignant melanomaOverall response rateMedian survivalComplete responsePartial responseSurgical resectionAdditional patientsMedian timeResidual tumorTreatment courseMalignant melanomaMarrow reconstitutionChemotherapyToxic reactionsPatientsResponse rateEntire groupMonthsDisease
1974
Potential for Prolonged Disease-free Survival Following Combination Chemotherapy of Non-Hodgkin’s Lymphoma
Schein P, Chabner B, Canellos G, Young R, Berard C, DeVita V. Potential for Prolonged Disease-free Survival Following Combination Chemotherapy of Non-Hodgkin’s Lymphoma. Blood 1974, 43: 181-189. PMID: 4589318, DOI: 10.1182/blood.v43.2.181.181.Peer-Reviewed Original ResearchConceptsComplete remissionMedian survivalCombination chemotherapyHodgkin's lymphomaExtended disease-free survivalDisease-free survivalImproved median survivalNon-Hodgkin lymphomaMOPP chemotherapyMedian durationFurther therapyNodular histologyHistologic subgroupsDiffuse histologyHistologic categoriesNodular patternAggressive subgroupClinical validityLymphomaAdvanced stageRemissionChemotherapyEntire groupPatientsSignificant differences
1973
Hodgkin's Disease in Childhood
Young R, DeVita V, Johnson R. Hodgkin's Disease in Childhood. Blood 1973, 42: 163-174. PMID: 4793108, DOI: 10.1182/blood.v42.2.163.163.Peer-Reviewed Original ResearchMAINTENANCE CHEMOTHERAPY FOR ADVANCED HODGKIN'S DISEASE IN REMISSION
Young R, Chabner B, Canellos G, Schein P, Devita V. MAINTENANCE CHEMOTHERAPY FOR ADVANCED HODGKIN'S DISEASE IN REMISSION. The Lancet 1973, 301: 1339-1343. PMID: 4122739, DOI: 10.1016/s0140-6736(73)91672-3.Peer-Reviewed Original ResearchConceptsMaintenance therapyIntermittent therapyAdvanced HodgkinMaintenance chemotherapyAdditional therapyComplete remissionInitial remissionMedian durationFurther therapyHodgkin's diseasePatientsTherapyRemissionEntire groupDiseaseChemotherapySignificant differencesSurvivalGroupPrednisoneRegimensComplicationsMustineVincristineInfectionCombination Chemotherapy and Survival in Advanced Hodgkin's Disease
Canellos G, Young R, Berard C, DeVita V. Combination Chemotherapy and Survival in Advanced Hodgkin's Disease. JAMA Internal Medicine 1973, 131: 388-390. PMID: 4569375, DOI: 10.1001/archinte.1973.00320090078008.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply